Home
Guidelines
Pathogens
Antimicrobials
Most cases of MDR-TB in children can be attributed to direct transmission of a MDR M. tuberculosis strain from a known adult MDR-TB case
Refer to MPS for further definition, general treatment principles, and contact tracing
MDR-TB should be treated only in designated centres with appropriate expertise
Seek expert advice prior to commencing treatment of drug-resistant TB in children
See below for general information regarding treatment of drug-resistant TB, which needs to be tailored to each case, depending on extent and severity of TB disease and unique clinical circumstances
First 6-8 Months
Following 12-14 Months
Fluoroquinolones
Although Fluoroquinolones are not approved for use in children in most countries, the benefit of treating children with MDR-TB with a fluoroquinolone may outweigh the risk in many instances
Second-line injectable agents
Other core second-line agents
Add-on agents
Not part of the core MDR-TB regimen
